This summary was created by AI, based on 19 opinions in the last 12 months.
Thermo Fisher Scientific (TMO) has faced challenges since its peak in late 2021, primarily due to inventory issues and a stagnant healthcare sector. Despite a recent decline and mixed quarterly results, many analysts remain optimistic about the stock's long-term prospects, noting its defensive qualities and steady dividend growth. Anticipation of a gradual improvement over the next couple of years aligns with a favorable shift in the healthcare industry, particularly with potential deregulation and renewed pharmaceutical spending. With a price-to-earnings ratio that appears attractive compared to historical averages, analysts suggest TMO might be undervalued currently. Additionally, ongoing share buybacks could reinforce shareholder confidence moving forward.
Has longed liked this and it's long been a good performer, but it has struggled since peaking in end-2021 and pulled back in 2022, and sideways ever since. TMO benefitted in 2020-1 as drug companies spent a fortune dealing with Covid and needed TMO's medical machines. From Oct. 2023 to Sept. 2024, shares rose 51%, but is down 18% since then. But they last reported a mixed quarter: a slight miss in revenue though a slight beat in earnings and soft guidance. It sold off and hasn't stopped, though announcing a $4 billion share buyback last month helped. He expects a graudal improvement as business picks up int he next two years. Trades at only 22x PE 2025 vs. 30x historically, so it's cheap now.
The merger doesn't take effect until Jan. 1; she see few changes after the merger. Price has disappointed post-Covid, given inventory and interest rate hurdles. With rates falling, she expected health care to resume, but she thinks that spend is delayed. The stimulus in China will help. With the new US president, we also don't know what will happen to this sector. But she likes TMO's fundamentals, and would buy at these levels.
Touches all aspects of bio-pharma industry. For example, helps run pharmaceutical trials, and helps build and design new drugs. Everything you need, such as electron microscopes, to create new drugs and products.
Weak coming out of Covid, as there was too much inventory in the system. Now primed to see revenue growth reaccelerate. Last time, Trump was favourable to healthcare and biotech. Low multiple relative to its historical average. Yield is 0.3%.
All the tools and services that the healthcare industry needs, so you get diversity with just the one stock. Very well managed. Long-term growth targets are 7-9%. Always improves margins. China is about 8% of revenues, a bit weaker. Biotech funding dried up with higher rates. Inventory destocking. Hopefully, those 3 factors are behind them.
Thermo Fisher Scientific is a American stock, trading under the symbol TMO-N on the New York Stock Exchange (TMO). It is usually referred to as NYSE:TMO or TMO-N
In the last year, 16 stock analysts published opinions about TMO-N. 15 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Thermo Fisher Scientific.
Thermo Fisher Scientific was recommended as a Top Pick by on . Read the latest stock experts ratings for Thermo Fisher Scientific.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
16 stock analysts on Stockchase covered Thermo Fisher Scientific In the last year. It is a trending stock that is worth watching.
On 2025-04-01, Thermo Fisher Scientific (TMO-N) stock closed at a price of $482.97.
2023 and 2024 were challenged due to overhang with inventory. Will benefit from talk of deregulation of healthcare in the US. In spite of flat pricing for products, dividends still grow between 11-20%. Defensive, high-quality name, sleep at night, just let it ride. Yield is 0.3%.
(Analysts’ price target is $643.86)